Stockscreener 앱 받기
1.9509
7.47%
0.1109
전일 마감가:
$1.84
열려 있는:
$1.89
하루 거래량:
524.19K
Relative Volume:
0.07
시가총액:
$584.19M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-1.3006
EPS:
-1.5
순현금흐름:
$-260.90M
1주 성능:
+8.65%
1개월 성능:
-7.16%
6개월 성능:
+54.48%
1년 성능:
+33.61%
1일 변동 폭
$1.872
$2.00
1주일 범위
$1.72
$2.00
52주 변동 폭
$0.8511
$2.73
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.935 | 555.51M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
112.17 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
373.68 | 140.01B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
75.58 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.51 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Pacific Biosciences's Q4 And Full-Year Revenue Improves - Nasdaq
Pacific Biosciences of California Inc (PACB) Q4 2025 Earnings Ca - GuruFocus
PacBio (PACB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Pacific Biosciences of California Q4 2025 Earnings Call Transcript - MarketBeat
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
Pacific Biosciences of California Q4 Earnings Call Highlights - MarketBeat
Pacific Biosciences of California (PACB) reports Q4 loss, beats revenue estimates - MSN
Earnings call transcript: Pacific Biosciences beats Q4 2025 forecasts By Investing.com - Investing.com Canada
PACB: Record consumable growth and SparkNex launch set stage for 8% revenue growth in 2026 - TradingView
PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025 - Finviz
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Announces Earnings Results - MarketBeat
Pacific Biosciences: Q4 Earnings Snapshot - kens5.com
PacBio (PACB) Surpasses Q4 Revenue Expectations Amid Strategic E - GuruFocus
PacBio (NASDAQ: PACB) lifts 2025 revenue but posts large restructuring-driven loss - Stock Titan
Pacific Biosciences of California joins iHope to expand genomic sequencing access - Traders Union
PacBio tech joins iHope to help rare disease patients get answers - Stock Titan
Valuation Update: Is Freedom Holding Corp in a bullish channelEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Pacific Biosciences: Fourth Quarter Earnings Overview - Bitget
How strong is Pacific Biosciences of California Inc. stock revenue growth2025 Stock Rankings & Risk Controlled Stock Alerts - mfd.ru
PacBio Earnings: What To Look For From PACB - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt - 富途牛牛
How The Narrative Around Pacific Biosciences Of California (PACB) Is Shifting As Assumptions Evolve - Yahoo Finance
Buyback Watch: Will BIIB benefit from sector rotationPortfolio Value Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Pacific Biosciences of California (PACB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Risk Recap: Can Pacific Biosciences of California Inc. reach all time highs this yearWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Pacific Biosciences showcases automation options at SLAS2026 - Traders Union
Pacific Biosciences Announces Interim Leadership Role Realignment - TipRanks
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Nigeria
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 7.7%Here's Why - MarketBeat
Pacific Biosciences Sees Strategic Maneuvers Amid Financial Woes - StocksToTrade
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Pacific Biosciences Strengthens Balance Sheet via Asset Sale - TipRanks
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
PacBio Completes Sale of Short-Read Sequencing Assets to Illumina for $48.1 Million - Quiver Quantitative
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Stock Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market - sharewise.com
Pacific Biosciences of California (PACB) Stock Analysis: Navigating Growth Potential Amidst Market Challenges - DirectorsTalk Interviews
Pacific Biosciences of California unveils HiFiSequencing turning points at FOG2026 - Traders Union
Analyst Downgrade: Will Pacific Biosciences of California Inc outperform during market ralliesPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation (NASDAQ:PACB) - Seeking Alpha
PacBio To Report Q4 And FY25 Financial Results In Feb - Nasdaq
Pacific Biosciences showcases HiFi sequencing at FOG2026 in London - Traders Union
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Sahm
Pacific Biosciences stock shows signs of recovery, Canaccord maintains Buy By Investing.com - Investing.com Canada
How The New Price Target Is Reframing The Story For Pacific Biosciences (PACB) - Yahoo Finance
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week HighTime to Buy? - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
0.67%
자본화:
|
볼륨(24시간):